ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.75
+0.21 (3.21%)
Feb 19, 2026, 2:14 PM EST - Market open
ImageneBio Revenue
Revenue (ttm)
$800.00K
Revenue Growth
-89.95%
P/S Ratio
87.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
71.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 9.16M | -6.46M | -41.35% |
| Dec 31, 2022 | 15.62M | -15.37M | -49.59% |
| Dec 31, 2021 | 30.99M | 21.79M | 237.01% |
| Dec 31, 2020 | 9.19M | -4.56M | -33.15% |
| Dec 31, 2019 | 13.75M | 12.76M | 1,289.19% |
| Dec 31, 2018 | 990.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NovaBay Pharmaceuticals | 10.30M |
| Spruce Biosciences | 697.00K |
| Coeptis Therapeutics Holdings | 501.00K |
| Seres Therapeutics | 351.00K |
| iBio, Inc. | 300.00K |
| MediciNova | 257.92K |
| Entera Bio | 124.00K |
IMA News
- 9 days ago - ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - GlobeNewsWire
- 3 months ago - ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - GlobeNewsWire
- 3 months ago - ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - GlobeNewsWire
- 7 months ago - ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 months ago - Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million - GlobeNewsWire
- 7 months ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire
- 7 months ago - Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewsWire
- 7 months ago - Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals - GlobeNewsWire